1. Adding Evidence to Frontline Hormone Receptor-Positive Breast Cancer Treatments

2. Introduction Advanced Hormone Receptor-Positive Breast Cancer

3. First-Line Endocrine Therapy in Advanced Breast Cancer Choice of ET ± CDK 4/6 Inhibitor

4. Visceral Crisis

5. FALCON Anastrozole vs Fulvestrant in Hormone Receptor-Positive Advanced Breast Cancer

6. FALCON Trial Results

8. Fulvestrant in ER-Positive Advanced Breast Cancer CONFIRM Phase 3, Double-Blind Trial

9. Comparison of Recent First-Line Studies for ER-Positive Advanced Breast Cancer

10. Overcoming Endocrine Resistance in Metastatic Breast Cancer

11. PALOMA-2 Palbociclib + Letrozole vs Letrozole Alone

12. MONALEESA-2 Ribociclib + Letrozole vs Letrozole in Hormone Receptor-Positive Advanced Breast Cancer

13. Palbociclib Management of Hematological Toxicities

14. How Do We Determine First-Line Therapy?

15. BOLERO-2 Everolimus + Exemestane vs Placebo + Exemestane

16. SWISH Trial Dexamethasone-Based Mouthwash for Stomatitis

17. Concluding Remarks

18. Abbreviations

19. Abbreviations (cont)